Please assess the completion status of the following clinical trial:

Trial Title: Short-Term Dual Antiplatelet and Maintenance CloPidogrel Therapy After Drug-Eluting Stent Implantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women at least 19 years of age~* Patients with stable coronary artery disease who were successfully treated with zotarolimus-eluting stents~* Patients without major bleeding or MACE (myocardial infarction, stent thrombosis, stoke, repeat revascularization) within 6 months after zotarolimus-eluting stent placement~* The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site.~Exclusion Criteria:~* Persistent thrombocytopenia (platelet count \<100,000/µl)~* A known intolerance to a study drug (aspirin, clopidogrel)~* Patients requiring long-term oral anticoagulants or cilostazol~* Patients presented with acute myocardial infarction (STEMI or NSTEMI) at the time of index procedure~* Planned cardiac surgery (e.g., CABG, valve repair or replacement, or aneurysmectomy) or planned major non-cardiac surgery within 18 months after procedure~* Bare-metal stent implantation at the time of index procedure~* Chronic disease requiring treatment with oral, intravenous, or intra-articular corticosteroids (use of topical, inhaled, or nasal corticosteroids is permissible).~* A diagnosis of cancer in the past 2 years or current treatment for the active cancer.~* Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the Investigator, would preclude safe completion of the study.~* Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation (ALT or AST \> 3 times upper limit of normal).~* History of adult asthma manifested by bronchospasm in the past 6 months, or currently taking regular anti-asthmatic medication(s).~* Unwillingness or inability to comply with the procedures described in this protocol.~* Patients pregnant or breast-feeding or child-bearing potential.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Short term dual therapy (Type: EXPERIMENTAL): None
- Long term dual therapy (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).